UOC
NVNO

UBS O'Connor’s enVVeno Medical NVNO Stock Holding History

UBS O'Connor’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,890
Closed -$962K – 401
2025
Q2 		$962K Sell
6,890
-1,568
-19% -$185K 0.03% 227
2025
Q1 		$779K Hold
8,458
– – 0.02% 204
2024
Q4 		$894K Hold
8,458
– – 0.02% 240
2024
Q3 		$995K Buy
8,458
+1,864
+28% +$342K 0.02% 276
2024
Q2 		$1.21M Buy
6,594
+128
+2% +$22.3K 0.03% 272
2024
Q1 		$1.23M Sell
6,466
-286
-4% -$51.3K 0.04% 255
2023
Q4 		$1.21M Buy
6,752
+286
+4% +$45.5K 0.04% 247
2023
Q3 		$1.22M Buy
6,466
+1,128
+21% +$188K 0.02% 308
2023
Q2 		$575K Buy
5,338
+263
+5% +$34.2K 0.01% 435
2023
Q1 		$840K Buy
5,075
+242
+5% +$45.2K 0.02% 428
2022
Q4 		$863K Buy
4,833
+555
+13% +$113K 0.02% 575
2022
Q3 		$940K Buy
4,278
+903
+27% +$192K 0.01% 753
2022
Q2 		$446K Buy
3,375
+1,160
+52% +$180K ﹤0.01% 823
2022
Q1 		$494K Buy
+2,215
New +$430K 0.01% 750

Other funds holding NVNO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS O'Connor's NVNO Position: Q3 2025 in Review

UBS O'Connor sold out of enVVeno Medical (NVNO) in Q3 2025, closing a stake of 6,890 shares — an estimated $962K sold.

UBS O'Connor first reported a position in NVNO in Q1 2022 and held it in 14 quarters. The position peaked at $1.23M in Q1 2024. 36 funds tracked by Wall St. Rank hold NVNO as of Q3 2025.

  • UBS O'Connor reported no remaining enVVeno Medical position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 6,890 enVVeno Medical shares in Q3 2025, an estimated $962K.
  • UBS O'Connor first reported a position in enVVeno Medical in Q1 2022 and held it in 14 quarters.
  • UBS O'Connor's enVVeno Medical position peaked at $1.23M in Q1 2024.
  • 36 funds tracked by Wall St. Rank held enVVeno Medical as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.